# Venclexta (venetoclax) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/venetoclax

> The FDA approved Venclexta (venetoclax), sponsored by AbbVie Inc. (ABBV), on April 11, 2016.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Venclexta (venetoclax) |
| Codes | ABT-199, GDC-0199 |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | [Chronic Lymphocytic Leukemia (CLL)](https://sec-api.dev/indications/chronic-lymphocytic-leukemia-cll), [Myelodysplastic Syndrome (MDS)](https://sec-api.dev/indications/myelodysplastic-syndrome-mds), [Multiple Myeloma](https://sec-api.dev/indications/multiple-myeloma), [Chronic Lymphocytic Leukemia](https://sec-api.dev/indications/chronic-lymphocytic-leukemia), Waldenstrom Macroglobulinemia, Acute Myeloid Leukemia (AML) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### April 11, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208573 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20160411, review_priority PRIORITY; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22

### October 16, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208573 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20201016, review_priority PRIORITY; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22
- openFDA Drugs@FDA: "NDA208573 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20201016, review_priority PRIORITY; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22

### October 4, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208573 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20211004, review_priority STANDARD; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22

### September 23, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Acute Myeloid Leukemia (AML); Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04161885 (A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-04." https://clinicaltrials.gov/study/NCT04161885

### October 9, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05105841 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-10-21." https://clinicaltrials.gov/study/NCT05105841

### February 19, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208573 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20260219, review_priority STANDARD; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22

### May 20, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208573 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20260520, review_priority STANDARD; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22

### August 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03539744 (A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT03539744

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03539744 (A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT03539744

### October 21, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05105841 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-10-21." https://clinicaltrials.gov/study/NCT05105841?tab=results

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Lymphocytic Leukemia (CLL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04895436 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04895436

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Lymphocytic Leukemia (CLL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04895436 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04895436

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02899052 (Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT02899052

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02899052 (Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT02899052

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Myelodysplastic Syndrome (MDS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04401748 (Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04401748

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Myelodysplastic Syndrome (MDS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04401748 (Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04401748

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia; Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03844048 (An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT03844048

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia; Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03844048 (An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT03844048

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Lymphocytic Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06428019 (A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06428019

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Lymphocytic Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06428019 (A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06428019

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Waldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07387471 (Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT07387471

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Waldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07387471 (Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT07387471

## Same indication

- [Calquence (acalabrutinib)](https://sec-api.dev/pdufa/acalabrutinib) (AZN)
- [Anitocabtagene autoleucel](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) (GILD)
- [APG2575](https://sec-api.dev/pdufa/apg2575) (AAPG)
- [Arlocabtagene autoleucel](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) (BMY)
- [BB2121](https://sec-api.dev/pdufa/bb2121) (BMY)
- [Belantamab mafodotin](https://sec-api.dev/pdufa/belantamab-mafodotin) (GSK)
- [Bexobrutideg](https://sec-api.dev/pdufa/bexobrutideg) (NRIX)
- [Cemsidomide](https://sec-api.dev/pdufa/cemsidomide) (CCCC)
- [Cilta-cel](https://sec-api.dev/pdufa/cilta-cel) (JNJ)
- [DARZALEX (daratumumab)](https://sec-api.dev/pdufa/daratumumab) (JNJ)
- [Empliciti (elotuzumab)](https://sec-api.dev/pdufa/elotuzumab) (BMY)
- [Elrexfio (elranatamab)](https://sec-api.dev/pdufa/elranatamab) (PFE)
- [Emavusertib](https://sec-api.dev/pdufa/emavusertib) (CRIS)
- [Etentamig](https://sec-api.dev/pdufa/etentamig) (ABBV)
- [Zenbexus (iberdomide hydrochloride)](https://sec-api.dev/pdufa/iberdomide) (BMY)
- [Imbruvica (ibrutinib)](https://sec-api.dev/pdufa/ibrutinib) (ABBV)
- [ABECMA (idecabtagene vicleucel)](https://sec-api.dev/pdufa/idecabtagene-vicleucel) (BMY)
- [Igi, 10%](https://sec-api.dev/pdufa/igi-10) (TAK)
- [Iopofosine i 131 single dose](https://sec-api.dev/pdufa/iopofosine-i-131-single-dose) (CLRB)
- [JNJ-79635322](https://sec-api.dev/pdufa/jnj-79635322) (JNJ)
- [Revlimid® (lenalidomide)](https://sec-api.dev/pdufa/lenalidomide) (JNJ)
- [Nemtabrutinib](https://sec-api.dev/pdufa/nemtabrutinib) (MRK)
- [PHE885](https://sec-api.dev/pdufa/phe885) (NVS)
- [Jaypirca (pirtobrutinib)](https://sec-api.dev/pdufa/pirtobrutinib) (LLY)
- [Pomalyst (pomalidomide)](https://sec-api.dev/pdufa/pomalidomide) (BMY)
- [Ramantamig](https://sec-api.dev/pdufa/ramantamig) (JNJ)
- [BEQALZI™ (sonrotoclax)](https://sec-api.dev/pdufa/sonrotoclax) (ONC)
- [Tacabrutideg](https://sec-api.dev/pdufa/tacabrutideg) (ONC)
- [Talquetamab](https://sec-api.dev/pdufa/talquetamab) (JNJ)
- [TECVAYLI (teclistamab)](https://sec-api.dev/pdufa/teclistamab) (JNJ)
- [Zilovertamab vedotin](https://sec-api.dev/pdufa/zilovertamab-vedotin) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/venetoclax.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Venclexta (venetoclax) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/venetoclax

```bibtex
@misc{secapidev_pdufa_venetoclax_20261116,
  title        = {Venclexta (venetoclax) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/venetoclax}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_venetoclax_20261116","title":"Venclexta (venetoclax) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/venetoclax","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
